57946-60-8

Usage

Uses

Used in Pharmaceutical Industry:
2-(2,2,2-TRIFLUOROETHOXY)ANILINE is used as a reactant for the preparation of 1,4-diarylpiperidinylmethylureas, which are anti-hyperlipidemic agents. These agents play a crucial role in the treatment and management of hyperlipidemia, a condition characterized by high levels of lipids in the blood, which can lead to cardiovascular diseases.
The use of 2-(2,2,2-TRIFLUOROETHOXY)ANILINE in the pharmaceutical industry is primarily due to its ability to contribute to the synthesis of compounds with potential therapeutic effects. Its unique structure allows for the development of new drugs that can help address various health concerns, particularly those related to lipid metabolism and cardiovascular health.

Upstream product

• 433-06-7 2,2,2-Trifluoroethyl p-toluenesulfonate 
• 87014-28-6 1-(2,2,2-trifluoroethoxy)-2-nitrobenzene 
• 88-75-5 2-hydroxynitrobenzene 
• 7439-89-6 iron 
• 1493-27-2 ortho-nitrofluorobenzene 

Downstream Products

• 178671-99-3 1-[2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine 
• 1143579-12-7 4-(3-methoxyphenyl)-1-[2-(2,2,2-trifluoroethoxy)phenyl]piperidine-4-carbonitrile 
• 917514-08-0 4-heptafluoroisopropyl-2-(2,2,2-trifluoroethoxy)aniline 
• 220383-36-8 1-[N-[2-(2,2,2-trifluoroethoxy)-phenyl]-2-aminoethyl]-4-(2-methoxyphenyl)-piperazine 
• 1027544-70-2 8-Chloro-4-(3-{4-[2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propylamino)-quinoline-3-carboxylic acid ethyl ester 
• 1025909-31-2 8-Chloro-4-(3-{4-[2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propylamino)-quinoline-3-carboxylic acid 
• 334930-12-0 1-[2-(2,2,2-trifluoroethoxy)-phenyl]-4-[3-(N-phthalimido)-propyl]-piperazine 
• 334930-13-1 1-(3-Aminopropyl)-4-[2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine 

Relevant academic research and scientific papers

BIARYL-CONTAINING COMPOUNDS AS INVERSE AGONISTS OF ROR-GAMMA RECEPTORS

The present invention relates to biaryl-containing inverse agonists of ROR-gamma receptors. The invention also provides pharmaceutical compositions comprising these biaryl- containing inverse agonists, and methods of modulating ROR-gamma receptors using these inverse agonists. Also provided are methods of using biaryl-containing inverse agonists to treat ROR-gamma mediated diseases.

AMIDE DERIVATIVE, PESTICIDE CONTAINING SUCH COMPOUND AND USE THEREOF

Disclosed are a compound represented by the general formula (1) below which exhibits a high insecticidal effect, and a pesticide containing such a compound as an active ingredient. (1) (In the formula, A1, A2, A3 and A4 respectively represent a carbon atom or the like; R1 and R2 respectively represent a hydrogen atom, an alkyl group or the like; G1 and G2 respectively represent an oxygen atom or the like; X represents a hydrogen atom, a halogen atom or the like; n represents an integer of 0-4; Q1 represents a substituted phenyl group, a substituted heterocyclic group or the like; and Q2 represents a phenyl group having a haloalkylthio group or the like, a heterocyclic group or the like.)

PYRROLO 3,2-c]QUINOLINE DERIVATIVES CONTAINING HALOALKOXY GROUP AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

The present invention relates to a novel pyrrolo[3,2-c]quinoline derivatives containing haloalkoxy group, represented by Formula I, their pharmaceutically acceptable salts; process for preparation thereof; and pharmaceutical composition thereof for treati

Pyrrolo [3,2-c] quinoline derivatives containing haloalkoxy group and pharmaceutically acceptable salts thereof

The present invention relates to a novel pyrrolo[3,2-c]quinoline derivatives containing haloalkoxy group, represented by Formula I, their pharmaceutically acceptable salts; process for preparation thereof; and pharmaceutical composition thereof for treati

PYRIMIDINEDIONE, PYRIMIDINETRIONE, TRIAZINEDIONE AND TETRAHYDROQUINAZOLINEDIONE DERIVATIVES AS ALPHA1-ADRENERGIC RECEPTOR ANTAGONISTS

Compounds of Formula I: STR1 where R 5 is a group selected from Formulae (a), (b), (c) and (d): STR2 and the pharmaceutically acceptable salts and N-oxides thereof, are α 1-adrenergic receptor antagonists useful for the treatment of diseases involving directly or indirectly an obstruction of the lower urinary tract, such as benign prostatic hyperplasia.

N-Arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective α1-adrenoceptor antagonists

Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype- selective antagonists by functional in vitro screening. 3-[4-(ortho- Substituted phenyl)piperazin-1:yl]propylamines were derivatized with N,N- dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4- b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta were used as a 'negative screen' for the test antagonists. Binding to α1-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure-affinity findings were exploited to produce nicotinamides (e.g. 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the α1-AR subtype prevalent in the human lower urinary tract (pA2 values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2-3 orders of magnitude selectivity over the α(1D)-AR.

Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists

The present invention relates to novel α1-adrenoceptor antagonists of the formula I*(formula 01)* in which: R1 is acetylamino, amino, cyano, trifluoroacetylamino, halo, hydro, hydroxy, nitro, methylsulfonylamino, 2-propynyloxy, a group selected from (C1-6)alkyl, (C3-6)cycloalkyl, (C3-6)cycloalkyl(C1-4)alkyl, (C1-6)alkyloxy, (C3-6)cycloalkyloxy, (C3-6)cycloalkyl(C1-4)alkyloxy and (C1-4)alkylthio (which group is optionally further substituted with one to three halo atoms) or a group selected from aryl, aryl(C1-4)alkyl, heteroaryl, heteroaryl(C1-4)alkyl, aryloxy, aryl(C1-4)alkyloxy, heteroaryloxy and heteroaryl(C1-4)alkyloxy (which aryl and heteroaryl are optionally further substituted with one to two radicals independently selected from halo and cyano); R2 is cyano, halo, hydro, hydroxy or a group selected from (C1-6)alkyl and (C1-6)alkyloxy (which group is optionally further substituted with one to three halogen atoms);R3 and R4 are both hydro or methyl or together are ethylene; and R5 is a group selected from Formulae (a), (b), (c) and (d):*(formula 02)* in which: X is C(O), CH2 or CH(OH); Y is CH2 or CH(OH); Z is N or C(R9), wherein R9 is hydro, (C1-6)alkyl or hydroxy; R6 is hydro, a group selected from (C1-6)alkyl, (C3-6)cycloalkyl, (C3-6)cycloalkyl(C1-4)alkyl (which group is optionally further substituted with one to three halo atoms) or a group selected from aryl, heteroaryl, aryl(C1-4)alkyl and heteroaryl(C1-4)alkyl (which aryl and heteroaryl are optionally further substituted with one to three radicals selected from halo, cyano, (C1-6)alkyloxy, (C1-6)alkyl and aryl); R7 is (C1-6)alkanoyl, carbamoyl, cyano, di(C1-6)alkylamino, halo, hydro, hydroxy, hydroxyiminomethyl, (C1-6)alkylsulfonyl, (C1-6)alkylthio, a group selected from (C1-6)alkyl, (C3-6)cycloalkyl,(C1-6)alkyloxy and (C1-6)alkyloxy(C1-4)alkyl (which group is optionally further substituted with one to three radicals selected from halo, hydroxy or (C1-6)alkyloxy) or a group selected from aryl, heteroaryl, aryl(C1-4)alkyl and heteroaryl(C1-4)alkyl (which aryl and heteroaryl are optionally further substituted with one to three radicals selected from halo, cyano, (C1-6)alkyloxy, (C1-6)alkyl and aryl) or R7 and R9 together are tetramethylene; and each R8 is independently hydro, hydroxy, methyl or ethyl; and the pharmaceutically acceptable salts and N-oxides thereof.